This is the authors' abstract. We don't add key points for this paper.
Activating signaling mutations are common in acute leukemia with KMT2A (previously MLL ) rearrangements ( KMT2A -R). These mutations are often subclonal and their biological impact remains unclear. Using a retroviral acute myeloid mouse leukemia model, we demonstrate that FLT3 ITD , FLT3 N676K , and NRAS G12D accelerate KMT2A - MLLT3 leukemia onset. Further, also subclonal FLT3 N676K mutations accelerate disease, possibly by providing stimulatory factors. Herein, we show that one such factor, MIF, promotes survival of mouse KMT2A - MLLT3 leukemia initiating cells. We identify acquired de novo mutations in Braf , Cbl , Kras , and Ptpn11 in KMT2A-MLLT3 leukemia cells that favored clonal expansion. During clonal evolution, we observe serial genetic changes at the Kras G12D locus, consistent with a strong selective advantage of additional Kras G12D . KMT2A-MLLT3 leukemias with signaling mutations enforce Myc and Myb transcriptional modules. Our results provide new insight into the biology of KMT2A -R leukemia with subclonal signaling mutations and highlight the importance of activated signaling as a contributing driver.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hyrenius‐Wittsten et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: